New possibility for lethal chikungunya virus treatment

1
New Possibility for Lethal Chikungunya Virus
Treatment?
2

• America based Inovio Pharmaceuticalss novel DNA-
  based monoclonal antibody(MAb) and DNA vaccine
  provided 100 protection to mice
  against lethalchikungunya virus (CHICV) in
  a preclinical study.

3

• The findings were published in The Journal of
  Infectious Diseases included this paper termed as
  Rapid and long term immunity elicited by DNA
  encoded antibody prophylaxis and DNA vaccination
  against chikungunya virus prepared
  by Inovio authors and their academic associates.

4

• Chikungunya is a mosquito transmitted viral
  disease, caused by a RNA virus that belongs
  to alphavirus genus the of family Togaviridae.
  The virus causes fatal fever with severe joint
  and muscle pain.

5

• In the course of years so many have
  faced chikungunya outbreaks such as Africa, Asia,
  Europe, and throughout the Indian and pacific
  oceans, with local transmission in over 43
  countries infecting millions of people. There is
  a notable increase in the cases and geographic
  spread of the disease.

6

• There has been a considerable increase in death
  rate caused by the disease, suggesting increased
  virulence. These potential harms caused by the
  virus calls for an antiviral interventions.

7

• Inovios patented dMAb technology encodes the DNA
  sequence for a specific monoclonal antibody in a
  DNA plasmid which would be directly delivered
  into the cells of the body by electroporation.

8
(No Transcript)
9

• Cells in the body would produce monoclonal
  antibody against the viral antigen present in the
  body, helping the body to recover and retaliate
  against the disease.

10

• Previous Inovio publication talked about SynCon,
  DNA vaccine for chikungunya virus provided
  durable 100 protection in mice. This study
  embodied a single intramuscular injection of
  a mABencoded DNA plasmid targeting chikungunya
  virus protected mice from a lethal dose of the
  virus.

11

• The protection expressed by dMAb antibodies was
  very quick, with 100 survival in mice challenged
  with lethal chikungunya virus. This protection
  was as early as two days after administration of
  dMAb vaccine.

12

• Current market for monoclonal antibody is well
  over 50 billion dollars. In the present
  scenario Inovios dMAb therapeutic technology may
  provide clear advantages over conventional
  monoclonal antibody technology and may
  revolutionize the existing trend by including
  faster development, easier product manufacturing,
  and more favorable pharmacokinetics.

13

• For More Update, Visit Us

http//medgenera.com/